Idoka

Sildenafil citrate, the active ingredient in Idoka, is a Phosphodiesterase type 5 inhibitor presented as a tablet for oral use. It is prescribed for the treatment of erectile dysfunction and pulmonary arterial hypertension in adult patients. GNH USA supplies Idoka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Idoka belongs to the phosphodiesterase type 5 inhibitor class and is used in conditions where vasodilation improves clinical outcomes.

Erectile dysfunction: enhances erectile response by increasing blood flow to the corpus cavernosum. Pulmonary arterial hypertension: improves exercise capacity and delays disease progression by relaxing pulmonary vascular smooth muscle.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often transient. - Flushing: warmth and redness of the face or upper body. - Dyspepsia: indigestion or upset stomach. - Nasal congestion: blocked or runny nose. - Visual disturbance: blurred vision or color tinge. - Back pain: muscular discomfort, usually self‑limiting.

Serious or Rare Side Effects: - Priapism: prolonged erection lasting more than four hours, requiring emergency care. - Sudden hearing loss: abrupt decrease or loss of hearing. - Severe hypotension: marked drop in blood pressure, especially with nitrates. - Non‑arteritic anterior ischemic optic neuropathy (NAION): sudden vision loss. - Myocardial infarction: heart attack in susceptible individuals.

Before prescribing Idoka, clinicians should evaluate specific risk factors and comorbidities. - Cardiovascular assessment: ensure patient can tolerate sexual activity. - Nitrate use: avoid concurrent use due to risk of severe hypotension. - Severe hepatic impairment: dose adjustment may be required. - Ocular conditions: caution in patients with retinal disorders. - Concomitant alpha‑blockers: monitor for additive blood‑pressure effects. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Idoka can interact with several medication classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Nitrates (e.g., nitroglycerin): may cause life‑threatening hypotension. - Guanylate cyclase stimulators (e.g., riociguat): additive vasodilatory effect. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase sildenafil exposure. - Certain protease inhibitors (e.g., ritonavir): elevate plasma levels. - Alpha‑blockers (high dose): risk of marked blood‑pressure drop.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Antihypertensive agents: possible additive blood‑pressure lowering. - Other PDE5 inhibitors: avoid concurrent use. - Alcohol: may enhance hypotensive effect. - Diuretics: monitor electrolytes and blood pressure.